Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing

Voyageur Pharmaceuticals Ltd. has achieved laboratory validation of its Mueller iodine extraction process, demonstrating 99.8% purity with greater than 90% recovery using real oilfield brine. The company has constructed a mobile, field-capable pilot unit with a capacity of 80,000 liters per day, with field testing scheduled for September 2026. This milestone marks the company's transition from bench-scale validation to continuous, real-world field operations.

A preliminary design for a 200 metric ton per year plant is complete, utilizing a modular strategy to deploy units at saltwater disposal sites. The long-term capacity target is 1,000 tonnes per year to support domestic iodine-based contrast pharmaceutical production. The clean brine byproduct generated by the process is suitable for disposal, reinjection, or Direct Lithium Extraction.

Voyageur Pharmaceuticals Ltd. (VM) confirmed technical progress that aligns with previous announcements regarding the Mueller process, which the company acquired in January 2026. Bench testing demonstrated a 90% yield to technical grade iodine, with achieving 99.8% purity in the lab identified as the logical next step.

The company expects to move to a field pilot, a transition intended to de-risk the technology incrementally. This development does not constitute a commercial breakthrough or revenue catalyst.

Voyageur Pharmaceuticals remains pre-revenue, heavily cash-burning, and under a going concern warning. The field pilot will require additional capital, increasing dilution risk.

The market likely priced in this technical milestone. The stock has consolidated between $0.10 and $0.15 since June 2026, suggesting limited immediate upside from this announcement alone.

Voyageur Pharmaceuticals Ltd. (VM) is a Canadian junior developing a vertically integrated supply chain for barium and iodine contrast media used in medical imaging. The company’s flagship projects include the Frances Creek barite project in British Columbia and the Mueller iodine extraction process in the Anadarko Basin, Oklahoma. Voyageur aims to become the only vertically integrated manufacturer of both barium and iodine contrast agents globally, a strategy it refers to as "Earth to Bottle."

Barium products are Health Canada-approved, with the first commercial delivery scheduled for August 2025. FDA 505(b)(2) submissions commenced in February 2026. The company’s iodine strategy relies on the acquired Mueller process, supported by a collaboration and milestone funding agreement with Bayer AG.